1-5 of 5
Satoshi Yoda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Open Access
Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola W. Zhu, Enriqueta Felip, Byoung Chul Cho, Luc Friboulet, Aaron N. Hata, Henry E. Pelish, Alexander Drilon
Journal: Cancer Discovery
Cancer Discov (2024) 14 (12): 2367–2386.
https://doi.org/10.1158/2159-8290.CD-24-0231
Published: 02 December 2024
View article titled, NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Open the PDF for NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations in another window
Includes: Supplementary data
Journal Articles

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Open Access
Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin
Journal: Cancer Discovery
Cancer Discov (2023) 13 (3): 598–615.
https://doi.org/10.1158/2159-8290.CD-22-0968
Published: 01 March 2023
View article titled, NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Open the PDF for NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations in another window
Includes: Supplementary data
Journal Articles

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Free
Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz, Justin F. Gainor, Inga T. Lennes, Viola W. Zhu, Nicolas Marcoux, Mandeep K. Banwait, Subba R. Digumarthy, Wenjia Su, Satoshi Yoda, Amanda K. Riley, Varuna Nangia, Jessica J. Lin, Rebecca J. Nagy, Richard B. Lanman, Dora Dias-Santagata, Mari Mino-Kenudson, A. John Iafrate, Rebecca S. Heist, Alice T. Shaw, Erica K. Evans, Corinne Clifford, Sai-Hong I. Ou, Beni Wolf, Aaron N. Hata, Lecia V. Sequist
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (12): 1529–1539.
https://doi.org/10.1158/2159-8290.CD-18-1022
Published: 03 December 2018
View article titled, Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Open the PDF for Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion in another window
Includes: Supplementary data
Journal Articles

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Free
Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman, Ted W. Johnson, Aaron N. Hata, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2018) 8 (6): 714–729.
https://doi.org/10.1158/2159-8290.CD-17-1256
Published: 31 May 2018
View article titled, Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Open the PDF for Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Free
Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth Lockerman, Tiffany Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba Digumarthy, Colleen Channick, Colleen Keyes, Gad Getz, Dora Dias-Santagata, Rebecca S. Heist, Jochen Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2016) 6 (10): 1118–1133.
https://doi.org/10.1158/2159-8290.CD-16-0596
Published: 02 October 2016
View article titled, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Open the PDF for Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer in another window
Includes: Supplementary data